Pharma Stability: Insights, Guidelines, and Expertise
Sorptive packaging materials absorb or adsorb drug product constituents such as preservatives, flavors, or even the API itself. Reactive packaging materials can chemically alter the drug product, leading to degradation or instability.
Click to read the full article.
According to USFDA and EMA guidelines, all materials and equipment used during product development and testing must be GMP-compliant. The packaging used for stability testing must:
Click to read the full article.
Packaging materials are in direct contact with the drug product throughout its shelf life. They can influence the product’s quality, safety, and efficacy. Regulatory agencies require manufacturers to demonstrate that these materials are suitable for use, have been properly tested, and are sourced from approved suppliers. Certification ensures that the packaging components:
Click to read the full article.
Permeability refers to the ability of gases or vapors to pass through a packaging material. For pharmaceutical applications, the key parameters are:
Click to read the full article.
Packaging stress tests are controlled evaluations used to determine how well packaging materials withstand harsh physical, thermal, and humidity conditions. Unlike routine shelf-life studies, stress tests push packaging to its limits to:
Click to read the full article.
Packaging serves as the first line of defense against environmental stressors like oxygen, moisture, light, and microbial ingress. Regulatory agencies such as the USFDA and ICH demand that container closure systems be validated and routinely monitored. Compromised packaging can invalidate stability data and jeopardize regulatory approvals.
Click to read the full article.
The physicochemical properties of the dosage form determine its susceptibility to degradation. Solid tablets may be vulnerable to moisture and oxidation, while liquid formulations require protection from microbial contamination, evaporation, and chemical instability. Hence, packaging material and design must align with the dosage form’s specific vulnerabilities.
Click to read the full article.
ICH Q1A(R2) states that the stability studies should be conducted using the same packaging system as intended for marketing. The packaging must protect the product’s physical, chemical, and microbiological attributes throughout its shelf life. According to Section 2.4 of the guideline, stability testing must evaluate the influence of the packaging on product quality.
Click to read the full article.
Light-sensitive drugs degrade through oxidation, isomerization, or cleavage when exposed to wavelengths between 300–800 nm. Regulatory agencies require evaluation of photostability during development, as outlined in ICH Q1B. Packaging must serve as a protective barrier to minimize this risk.
Click to read the full article.
Packaging must preserve the identity, strength, quality, and purity of the drug under ICH-specified conditions. Evaluations are needed to ensure:
Click to read the full article.
Don’t leave empty-handed. Watch practical GMP scenarios, inspection lessons, deviations, CAPA thinking, and real compliance insights on our YouTube channel. One click now can save you hours later.